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ABSTRACT
Human papillomaviruses (HPVs) including high-risk
(HR) and low-risk (LR) subtypes have distinguishable
variation on both genotypes and phenotypes. The co-
infection of multiple HR-HPVs, headed by HPV16, is
common in cervical cancer in female. Recently accu-
mulating reports have focused on the interaction be-
tween virus and host, particularly the role of human
microRNAs (miRNAs) in anti-viral defense by targeting
viral genome. Here, we found a well-conserved target
site of miRNAs in the genomes of most HR-HPVs, not
LR-HPVs, by scanning all potential target sites of human
miRNAs on 24 HPVs of unambiguous subtypes of risk.
The site is targeted by two less common human miR-
NAs, miR-875 and miR-3144, and is located in E6 onco-
gene open reading frame (ORF) and overlap with the ﬁrst
alternative splice exon of viral early transcripts. In
validation tests, miR-875 and miR-3144 were identiﬁed
to suppress the target reporter activity markedly and
inhibit the expression of both synthetically exogenous
E6 and endogenous E6 oncogene. High level of two
miRNAs can inhibit cell growth and promote apoptosis
in HPV16-positive cervical cancer cells. This study pro-
vides a promising common target of miRNAs for most
HR-HPVs and highlights the effects of two low ex-
pressed human miRNAs on tumour suppression.
KEYWORDS human papillomavirus, microRNA, E6,
miR-875, miR-3144
INTRODUCTION
MicroRNAs (miRNAs) are small non-coding RNAs that
modulate gene expression at post-transcriptional level for
degradation of the target mRNAs or inhibiting translation of
the encoded protein, playing critical roles in a wide spectrum
of biological processes (Ambros, 2004). They bind to com-
plementary target sites in mRNA that are often located in 3′
untranslated region (UTR) but can also be found in 5′UTR or
even coding region (Forman and Coller, 2010; Li et al.,
2011). Recent data provide increasing evidence that human
miRNAs may directly affect viral gene expression contribut-
ing to host’s innate anti-viral defense or viral immune escape
(Ghosh et al., 2009; Mahajan et al., 2009). In 2005, one
human miRNA (has-miR-32) was reported to be able to
target sequence in primate foamy virus type 1 (PFV-1)
genome thereby inhibiting viral replication and translationLin Lin and Qingqing Cai have contributed equally to this work.
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(Lecellier et al., 2005). Currently, more and more human
miRNAs that target hepatitis C virus (HCV), hepatitis B virus
(HBV), human immunodeﬁciency virus (HIV), inﬂuenza A
Virus H5N1 and H1N1 were found (Houzet et al., 2012;
Pedersen et al., 2007; Potenza et al., 2011; Scaria et al.,
2006; Song et al., 2010). It is noted that many of these target
sequences, such as the target of miR-125 in HBV, the tar-
gets of miR-448 and miR-122 in HCV (Li et al., 2011; Ped-
ersen et al., 2007; Potenza et al., 2011), were found well
conserved through viral genomes, and several of them have
been preferentially exploited for new anti-viral strategies
(Russo and Potenza, 2011).
Human papillomaviruses (HPVs) are non-enveloped, dou-
ble-stranded circular DNA viruses and are associated with a
wide spectrum of benign and malignant neoplasia (Zheng and
Baker, 2006). Until now, more than 120 HPV subtypes have
been identiﬁed and characterized (Bernard et al., 2010). Ac-
cording to oncogenic potentials epidemiologically, some of
them are classiﬁed into “high-risk (HR)” group and “low-risk
(LR)”group (Munozet al., 2003). Persistent infectionofmultiple
HR-HPVs is the major cause of cervical cancer in female. As a
representative HR-HPV, HPV16 is responsible for ap-
proximately ∼60% of invasive cervical cancers worldwide
(Zheng and Baker, 2006). HR-HPVs bound up with malignan-
cies have developed many oncogenic strategies which are
rarely found in LR-HPVs. Examples include that viral crucial
oncoproteins efﬁciently degrade tumor suppressors (such as
E6 target p53) (Scheffner et al., 1990), and integration of the
viral DNA segments into the human genome increases E6
expression leading to oncogenesis (Alp Avci, 2012).
While the role of miRNAs in cervical cancer, as well as in
other cancers, has been extensively studied during the past
few years (Hayes et al., 2014; Jimenez-Wences et al., 2014),
few miRNAs have been reported to be involved in the
regulation of HPV viral life cycle, and those researches were
based on limited HR-HPV subtypes (Gunasekharan and
Laimins, 2013; Jung et al., 2014; Melar-New and Laimins,
2010; Nuovo et al., 2010). Since co-infection of multiple HR-
HPVs is common in cervical cancer (Mejlhede et al., 2010),
we wondered that whether there are some human miRNAs
who can target the majority of HR-HPVs. Our previous study
found that HPVs in different group with speciﬁc oncogenic
potential (HR or LR group) have distinguishable divergence
on phylogenetic genotypes (Li et al., 2009). We also noticed
that miRNAs are conserved, and are promising phylogenetic
markers for interpreting evolution of organisms (Qingqing
Cai, 2010). Therefore, it seems possible to ﬁnd some can-
didate miRNAs and conserved target sites distinguishable
between HR-HPVs and LR-HPVs.
In this study, we employed bioinformatics approaches to
look for potential conserved target among the majority of HR-
HPV genomes for human miRNAs and investigate the target
effects of candidate miRNAs on HPV oncogene and cervical
cancer cells. It might provide a promising common target of
miRNAs for most HR-HPVs and focus on the effects of two
low expressed human miRNAs on tumour suppression.
RESULTS
In silico analysis yielded most promising target sites
of human miRNAs in HPV genome
15 HR-HPV subtypes (HPV16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59, 68, 73, and 82) and 9 LR-HPV subtypes
(HPV6, 11, 40, 42, 43, 44, 54, 61, and 81) were obtained
from PaVE: Papilloma virus genome database (http://pave.
niaid.nih.gov/). Sequences were allocated according to
genes and regions annotation and formed 8 representing
regions including E1, E2, E4, E6, E7, L1, L2, and URR
which existed in almost all types of HPVs. The sequences
of each gene or region were aligned by MUSCLE with
default parameters. All sequences were subjected to
scanning for the putative binding sites of 2042 human
mature miRNAs by miRanda. Firstly, we calculated the
presumed binding efﬁciency between HR-HPV group and
LR-HPV group of each gene (or URR) region roughly: If a
miRNA has (at least) one binding site on a gene part in one
HPV subtype, we noted the binding situation as 1 (existing),
otherwise we noted as 0 (none). Then binding efﬁciency
was summarized according to HPV risk groups. For ex-
ample, miR-4282 was predicted to bind L1 genes of 15
HPV subtypes. Then the binding efﬁciency of miR-4282
and L1 were recorded as 15 (13 for HR-HPVs, while 2 for
LR-HPVs). Top 12 miRNAs who demonstrated a strong
preference for either risk group (the utmost absolute dif-
ference between HR-HPVs and LR-HPVs) was listed in
Table 1. In order to study the binding pattern, the binding
sites of 12 selected miRNAs were mapped to HPV align-
ments. Amazingly, most of the binding sites were randomly
located among HPVs or formed small conservation sites,
while the potential targets of miR-875 and miR-3144 lo-
cated in E6 oncogene ORF happened to form a conserved
target site almost unique in HR-HPVs as was shown in
Fig. 1. For HPV16, miR-875 was supposed to target seg-
ment nt 209–231 and miR-3144 was supposed to target
segment nt 207–232. The detailed sequences were showed
in Table 2.
MiR-875 and miR-3144 target the HPV genomic sites
in luciferase reporter
As bioinformatics analysis yielded the most promising target
sites of human miRNAs in HPV genome, it was important to
determine if the seed sequences actually functioned as tar-
get for these miRNAs. The most common and direct meth-
ods for miRNA target validation are based on ﬂuorescent
reporter gene constructs transfected in cultured cells (Kuhn
et al., 2008). The HPV genomic segments containing puta-
tive target sites for miR-875 and miR-3144 were then indi-
vidually cloned downstream of the Renilla luciferase open
reading frame contained in the psiCheck-2 vector as re-
porter. These luciferase reporters were subsequently trans-
fected into C33A cells along with miRNA expression vectors
and assayed for luciferase expression. The results obtained
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from two independent experiments, expressed as Renilla
luciferase activity relative to that of control ﬁreﬂy luciferase,
are shown in Fig. 2. In C33A cells, co-transfection with miR-
875 and its target (209–231) decreased the relative lu-
ciferase activity to 49% compared with empty pSilencer4.1-
CMV vector and target, and co-transfection with miR-3144
Figure 1. The sequence alignments for 15 HR-HPV subtypes (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82) and 9
LR-HPV subtypes (HPV6, 11, 40, 42, 43, 44, 54, 61, 81). Yellow highlights the targets of miR-875, red highlights the targets of miR-
3144, orange show their overlapping districts. Blue shows the degree of conservation in each Nucleotide site. The more conserved it
is, the darker blue it shows. Black columns at the bottom show the consensus of conservation in each Nucleotide site.
Table 1. Most differentiated binding situation between HR-HPV group and LR-HPV group








1 E6 MiR-875 13 13 0 13
2 E6 MiR-3144 12 12 0 12
3 L1 MiR-4282 15 13 2 11
4 E1 MiR-2355 13 12 1 11
5 E1 MiR-365 11 11 0 11
6 L2 MiR-889 20 15 5 10
7 E1 MiR-626 18 14 4 10
8 E2 MiR-302a 14 12 2 10
9 E2 MiR-2355 14 12 2 10
10 E1 MiR-26b 12 11 1 10
11 L2 MiR-3665 12 11 1 10
12 L1 MiR-1299 10 10 0 10
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and its target (207–232) decreased the activity to 71%
compared to empty vector and target. To examine whether
the interaction between miRNAs and their target sequences
direct or indirect, we mutated the miRNA binding sites with
one or two nucleotide mutations (Table 2). As a result, with
those mutation presented in reporter (Δ209–231, Δ207–232),
luciferase expression failed to be regulated by miR-875 and
miR-3144 (Fig. 2). These experiments demonstrated that
miR-875 and miR-3144 interacted directly with their binding
sites to regulate luciferase reporter expression, and the ef-
fect was supposed to be highly speciﬁc, as it was abolished
when the target sequence was single-nucleotide or two-nu-
cleotide mutated.
MiR-875 and miR-3144 negatively regulate exogenous
E6 gene expression
MiRNAs can suppress the expression of target genes
through translational repression or through degradation of a
target’s transcript. Since miR-875 and miR-3144 can down-
regulate the luciferase expression by binding to their target in
E6, we investigated whether the two miRNAs could directly
Table 2. Sequences and names of constructed plasmids
Name Sequences Vector Constructed plasmids
MiR-875 UAUACCUCAGUUUUAUCAGGUG pSilencer4.1-CMV MiR-875
Expression vector
Target: 209–231 nt* CAGTTACTGCGACGTGAGGTATA psiCheck-2 209–231
Luciferase reporter
Mutated target CAGTTACTGCGACGTGAGGATTA psiCheck-2 Δ209–231
Mutated reporter
MiR-3144 AUAUACCUGUUCGGUCUCUUUA pSilencer4.1-CMV MiR-3144
Expression vector
Target: 207–232 nt* AACAGTTACTGCGACGTGAGGTATAT psiCheck-2 207–232
Luciferase reporter
Mutated target AACAGTTACTGCGACGTGAGGATTAT psiCheck-2 Δ207–232
Mutated reporter
E6 NC_001526, nt 83–559 (498 bp)** pcDNA3.1 pcDNA3.1-E6
* Sites in HPV16 genome.














































































Figure 2. MiR-875 and miR-3144 inhibit luciferase reporter expression. (A) Analysis of the relative luciferase activity in C33A
cells co-transfected with miR-875 vector and target (209–231) reporter, or empty vector and target (209–231) reporter, or miR-875
vector and mutated target (Δ209–231) reporter. (B) Analysis of the relative luciferase activity in C33A cells co-transfected with miR-
3144 vector and target (207–232) reporter, or empty vector and target (207–232) reporter, or miR-3144 vector and mutated target
(Δ207–232) reporter. P-values at Student’s t-test were *P < 0.05.
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regulate E6 expression. We transfected synthetically E6
construct (pcDNA3.1-E6) into HPV-negative cervical carci-
noma cell lines (C33A). Although E6 gene is transcribed
through bicistronic E6/E7 mRNA, studies show that trans-
fection with monocistronic E6 into C33A cells could also
result in a stable expression of unspliced E6 mRNA (del
Moral-Hernandez et al., 2010). Some of these cells were
then transfected with miRNAs expression vectors or empty
pSilencer4.1-CMV vector. Then quantitative real-time RT-
PCR was used to quantitate the E6 mRNA level in all group
cells. The results obtained from this experiment, expressed
as relative expression normalized with internal control gene
homo-Actin. As shown in Fig. 3, transfection with syn-
thetically E6 construct (E6) or along with empty pSi-
lencer4.1-CMV vector (vector + E6) result in stable
expression of E6 mRNA, while transfection with E6 construct
along with miR-875 (miR-875 + E6) or miR-3144 (miR-
875 + E6) individually decreased the expression of E6
mRNA to 53% or 42%.
MiR-875 and miR-3144 negatively regulate endogenous
E6 gene expression
The experimental model above was used to measure the
repression effect on exogenous E6, we further investigated
whether miR-875 and miR-3144 could interfere with the ex-
pression of endogenous E6 oncogene. MiR-875 and miR-
3144 expression vectors were then transfected into cervical
cancer SiHa cells which contain integrated HPV16 DNA and
have detectable level of E6 oncogene mRNA (Rosenberger
et al., 2010). Empty pSilencer4.1-CMV vector (Vector) and
untreated SiHa cells (Mock) were used for controls. As
shown in Fig. 4A, the expression levels of miR-875 and miR-
3144 in SiHa cells after transfection obtained by RT-qPCR
were signiﬁcantly increased compared to controls. The RT-
PCR was then used to detect the average cellular content of
E6 oncogene mRNA. As shown in Fig. 4B and 4C, trans-
fection with miR-875 decreases the cellular content of E6
mRNA by 26.0% compared to Mock control and 26.4% to
Vector control. Likewise, transfection with miR-3144 de-
creases the E6 mRNA by 30.5% compared to Mock control
and 25.3% to Vector control. The regulation was believed to
be remarkable if we consider the possible pre-existing ex-
pression of other endogenous targets of the two miRNAs, as
one miRNA always target more than one gene. Taken to-
gether, these results indicated that miR-875 and miR-3144
negatively regulate not only exogenous E6 gene expression
from synthetic construct but also endogenous E6 oncogene
expression in an in vitro model through mRNA degradation.
High level of miR-875 and miR-3144 inhibit cell growth
in SiHa cells
In order to detect the effect of increased level of miR-875 or
miR-3144 on cancer cell growth, miR-875 and miR-3144 ex-
pression vectors were individually transfected into SiHa cells
and the increased levels of the twomiRNAswere conﬁrmedby
RT-qPCRasdescribed previously.Untreated cells (Mock) and
cells transfected with empty vector (Vector) were used for
controls. The xCELLigence RTCA System was then per-
formed to monitor the proliferative potential of those cells. In
this system, the growth rate of cells was measured by
monitoring the cell index which depend on the electronic
readout of cell sensor impedance with real-time and con-
tinuous record every 4 h. After 120 h of monitoring cell prolif-
eration with this System, we observed a continuous decrease
of cell growth and motility in both miR-875 transfected cells
and miR-3144 transfected cells. Instead, those cells in two
control groups continued to grow smoothly during this period
(Fig. 5), suggesting that overexpression of miR-875 and miR-
3144 could inhibit the growth of cervical cancer cells.
High level of miR-875 and miR-3144 induces apoptosis
in SiHa cells
In order to determine whether increased level of miR-875 or
miR-3144 induce apoptosis of cervical cancer cell, ﬂow cy-
tometric analysis of cell apoptosis was performed for SiHa
cells transfected with miR-875 or miR-3144 expression
vectors, SiHa cells transfected with empty vectors (Vector)
and untreated SiHa cells (Mock). As shown in Fig. 6A, SiHa
cells in two control groups were primarily Annexin V/pro-
pidium iodide (PI) negative and remained viable, but the
SiHa cells with transfection of miR-875 and miR-3144 vec-
tors were observed to undergo apoptosis in both early and
late periods, which were shown by Annexin-V+/PI- for early
apoptotic stage and annexin-V+/PI + for late apoptotic stage.
And the rate of early apoptosis, late apoptosis and total
apoptosis were calculated and shown in Fig. 6B. The results
showed that overexpression of miR-875 and miR-3144 can




































Figure 3. MiR-875 and miR-3144 decrease the expression of
exogenous E6. The relative expression of E6 mRNA obtained
by qRT-PCR in C33A cells after co-transfection with synthetical-
ly E6 construct along with miRNAs vectors or empty vector. P-
values at Student’s t-test were *P < 0.05.
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The effects of overexpression of miR-875 and miR-3144
on nuclear morphology were measured by Hoechst 33258
staining, since the morphological changes in the nuclear
chromatin is indicative of the apoptotic process. As shown in
Fig. 7A, SiHa cells with transfection of miR-875 and miR-
3144 vectors exhibited reduced nuclear size, intense
ﬂuorescence, chromatin condensation, nuclear fragmenta-
tion, and presence of apoptotic bodies evident and were
considered apoptotic cells. As shown in Fig. 7B, the per-
centage of cells with apoptotic morphology was signiﬁcantly
increased in with miR-875 and miR-3144 transfected cells,
compared with cells in two control groups.
DISCUSSION
Cervical cancer, which is caused by persistent infection with
high-risk HPVs, is the second most common type of cancer
in women worldwide (Stewart and Wild, 2014). While recent
reports have highlighted the role of miRNAs as critical ef-
fectors in intricate host-virus interaction networks, we ad-
dress whether human miRNAs inﬂuence HPV oncogene in
this study. We employed bioinformatics approaches scan-
ning all potential targets of human miRNAs on 24 unam-
biguous risk-type HPVs. A well-conserved target site among
most HR-HPVs of two candidate miRNAs, miR-875 and miR-
3144, has been found. By using the luciferase reporter,
synthetically constructs and cultured cells, we show that
miR-875 and miR-3144 can cause silencing effect of target
reporter and interfere with the expression of E6 oncogene. In
the presence of high-level miR-875 and miR-3144, HPV-
positive cervical cancer cells undergo apparent growth re-
tardation and apoptosis promotion.
The targets of miR-875 and miR-3144 were found located


























































































































Figure 4. Transfection with miR-875 and miR-3144 interferes the expression of endogenous E6. (A) The expression levels of
miR-875 or miR-3144 by qRT-PCR in SiHa cells transfected with miR-875 or miR-3144 expression vectors, SiHa cells transfected
with empty vectors (Vector), or untreated SiHa cells (Mock). (B and C) RT-PCR analysis of E6 mRNA relative expression in SiHa cells
transfected with miR-875 or miR-3144 expression vectors, SiHa cells transfected with empty vectors (Vector), or untreated SiHa cells
(Mock). P-values at Student’s t-test were *P < 0.05, ***P < 0.001.
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associated with oncogenicity of HR-HPVs. E6 oncoprotein
was known to be able to directly target and degrade the
tumor suppressor p53, therefore inhibit p53-mediated
apoptosis, reduce p21-mediated cell cycle regulation, and
destabilize chromosomes, favoring tumor progression of
cervical cancer (Hausen, 2002). In this study, we demon-
strated that miR-875 and miR-3144 could suppress the ex-
pression of both exogenous E6 and endogenous E6 by
directly targeting E6 ORF. It should be noted that the ﬁrst
alternative exon of HR-HPVs’ early transcripts in E6 ORF
region can be alternatively spliced and lead to at least four
species of mRNA transcripts with various coding potential in
HPV16 (5′ splice site at 226 nt and three alternative 3′ splice
site at 409 nt, 526 nt, or 742 nt) (Zheng and Baker, 2006).
Among them, only un-spliced E6 full-length transcript en-
codes E6 oncoprotein and exhibit transforming capacity,
whereas other spliced transcripts E6* counteract E6 onco-
protein functions (Filippova et al., 2007; Pim and Banks,
1999). The target sites of miR-875 and miR-3144 in this
study were found overlap to this alternative splice exon and
thereby target only full-length transcript of E6 but no other
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Figure 5. High-level of miR-875 and miR-3144 inhibit cell growth. Time kinetics of cell growth after 120 h of monitoring every 4 h
with the xCELLigence RTCA DP System in SiHa cells transfected with miR-875 (A) or miR-3144 (B) vectors, or with empty vectors
(Vector), or untreated SiHa cells (Mock). P-values at Student’s t-test were *P < 0.05, ***P < 0.001.
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study cover the 5′ splice site which only exists in un-spliced
transcript of E6, our data support that miR-875 and miR-3144
interfere with expression of E6 full-length transcript, the latter
was considered as the only source of the E6 oncoprotein
(Stacey et al., 1995). Interestingly, alternatively spliced E6
transcripts have so far only been described for HR-HPVs but
not for LR-HPVs (Hernandez-Lopez and Graham, 2012), im-
plying that this region may have functional relevance on
biological processes of HR-HPV carcinogenesis. Since we
have little knowledge on the regulation of HPV at the level of
RNA splicing (Zheng and Baker, 2006), whether the reason
why the targets of miR-875 andmiR-3144 precisely overlap to
this region is a coincidence or that they are involved in
regulation of alternative splicing is not yet known.
So far, little is known about the biological function of miR-
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Figure 6. High-level of miR-875 and miR-3144 promoted cell apoptosis. (A) Annexin-V/PI analysis in SiHa cells transfected with
miR-875 or miR-3144 vector, or with empty vectors (Vector), or untreated SiHa cells (Mock). (B) Early apoptosis, late apoptosis and
the sum total of apoptosis in different group cells. P-values at Student’s t-test were *P < 0.05, **P < 0.01.
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6q22.31, a common fragile site in which HPV16 integration
happens frequently) (Thorland et al., 2000; Zhao et al.,
2012), which were ﬁrst reported publicly in 2007 and 2010
respectively (Landgraf et al., 2007; Stark et al., 2010). Both
of them have previously been reported by Daniela Witten
and his colleagues to be expressed at rather low levels in
human cervical tumor tissues, including squamous cell car-
cinoma tissue and adenosquamous cell carcinoma tissue,
with median expression 1.5 reads observed for miR-875 and
1 reads observed for miR-3144 (Witten et al., 2010). Based
on our observations, it is reasonable to explain that a suit-
able low level of miRNAs with antiviral effect is beneﬁcial for
HPV’s survival and persistent latency favoring carcino-
genesis. Moreover, miR-875 and miR-3144 have also been
reported to be dysregulated in several types of cancer, such
as pancreatic cancer, clear cell renal cell cancer, prostate
cancer, colorectal cancer, and upper tract urothelial cancer
(Hamfjord et al., 2012; Hao et al., 2011; Nguyen et al., 2013;
Weng et al., 2010; Zaravinos et al., 2014). Similar to the
present study, miR-875 was considered as one of the 14
candidate miRNAs which potentially target EGFR and act as
the therapeutic target of lung cancer in Lawrence WC Chan’s
study (Chan et al., 2012), and miR-875 was also linked to
cell apoptosis pathways in dopaminergic neuronal cells and
severe H1N1 viral infected cells (Juan Moran, 2014; Li et al.,
2013). Taken together, although only a few studies have
been done on the function of miR-875 and miR-3144, evi-
dence regarding miR-875 or miR-3144 mediated tumor
suppression is beginning to emerge.
However, the biological role of this effect on natural HPV
carcinogenesis remains unclear. It may be insufﬁcient to
eliminate the viruses but only counteract viral replication to
evade immune elimination and establish a persistent infec-
tion with a long host survival and a high spread of the virus in
the human population, like HBV, HCV, and HIV-1 (Russo and
Potenza, 2011). Therefore, forced high level of miR-875 and
miR-3144 in HPV-positive cervical cancer cells as we show
in this study could unbalance the HPV-host coexistence and
may re-direct the outcome from a persistent HR-HPV infec-
tion to a complete recovery.
This study adds to the growing body of evidence impli-
cating the association between miRNA and HPV in car-
cinogenesis. Aberrant cellular miRNAs expression proﬁles in
HPVs infected cervical cancer tissue or cell have been re-
ported (de Freitas et al., 2014). Several host miRNAs can be
modulated by oncogenic HPVs (Greco et al., 2011; Martinez
et al., 2008; Shi et al., 2012; Zheng and Wang, 2011). HPVs
were found to encode their own miRNA species lately (Qian
et al., 2013). However, limited investigations refer to the in-
terplay between HPV genes and miRNAs. Until recently,
B

































Figure 7. High-level of miR-875 and miR-3144 induced apoptotic morphological changes. (A) Apoptotic morphological changes
(white arrows) with Hoechst staining (blue) in ﬂuorescence microscope (200 × times) in SiHa cells transfected with miR-875 or miR-
3144 vector, or with empty vectors (Vector), or untreated SiHa cells (Mock). (B) Histograms for quantiﬁcation of the cell death (%) in
different groups. P-values at Student’s t-test were ***P < 0.001.
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some miRNAs were suggested to be involved in HPV
regulation which were based on limited HPV subtypes,
shown by that miR-203 have inhibitory effect on HPV16 DNA
replication, miR-125b and miR-145 suppress HPV31 ampli-
ﬁcation, and miR-375 interact with E1 and E7 gene of
HPV16 (Gunasekharan and Laimins, 2013; Jung et al.,
2014; Melar-New and Laimins, 2010; Nuovo et al., 2010).
This work provides two less common human miRNAs who
can target HPV16 E6 oncogene which the target site is a
promising common target for most HR-HPVs. So far,
therapeutics for clearing persistent HR-HPV infection are still
very limited (Harper and Demars, 2014). The optimal anti-
HPV strategy should be against multiple HR-HPV subtypes,
since co-infection is rather common in cervical cancer (Me-
jlhede et al., 2010). Although this study is preliminary with
only in vitro experiments, we believe the results add to the
novel knowledge for anti-HPV strategies.
While the prevailing wisdom is that miRNAs bind to the
3′UTR of target genes, this study shows that miR-875 and
miR-3144 bind to the coding region of E6. The possible
explanation is that HPV genome is limited and 3′UTR
sequence is not long enough. Likewise, evidence in some
other viruses, like HBVand HCV, reveals that coding region or
5′UTR could be targeted by miRNAs (Li et al., 2011; Potenza
et al., 2011). Moreover, our result is consistent with Anita
Dreher’s assumption that 3′UTR in HPV genomemight be not
a target formiRNA regulation (Dreher et al., 2011). Zheng et al.
have hypothesized that several dozen potentialmiRNAbinding
sites exist in the genome-wide distribution of HPV (Harper and
Demars, 2014), suggesting a need for further investigation to
unveil more cellular miRNA-mediated regulation of HPV.
MATERIALS AND METHODS
Materials
The psiCheck-2 vector was purchased from Promega. The pSi-
lencer4.1-CMV vector and pcDNA3.1 vector were obtained from
Ambion. DNA oligonucleotides were obtained from Invitrogen. The
HPV 16-positive SiHa cervical cancer cell line and HPV-negative
C33A cervical cancer cell line were used in this study.
Computational analyses
The standard viral genome sequences were obtained from PaVE:
Papilloma virus genome database (http://pave.niaid.nih.gov/). All
human mature miRNA sequences were obtained from miRBase Re-
lease 14.0 (http://www.mirbase.org/) (Grifﬁths-Jones et al., 2008).
Alignment of the DNA sequences of the viral genomeswas performed
with MUSCLE 3.6. The miRanda-3.3a was used to scan the HPV
genomic sequence for the potential target sites for miRNAs (John
et al., 2004). The modes of hybridization in computer programs were
based on the principles of miRNA-target recognition containing the
followingparameters: complementarity on local basepairs, RNA-RNA
double chain free energy, hybridization temperature, conservation of
the site, and miRanda score (Bentwich, 2005).
Plasmid constructs
Nucleotide sequences of putative miRNAs binding sites in HPV were
obtained by chemical synthesis of complementary oligonucleotides
and were cloned into psiCheck-2 vectors at XhoI and NotI sites as
luciferase reporter. The mutated target luciferase reporter bearing
single-nucleotide or two-nucleotide mutated target sequences were
obtained by the same approach. Human miRNA precursors were
cloned into pSilencer4.1-CMV vectors at BamHI and HindIII sites to
construct miRNA expression vectors. A 498 bp fragment containing
full-length E6 ORF of HPV16 (NC_001526, nt 83–559) were ampli-
ﬁed by PCR and cloned into pcDNA3.1 vector at NheI/XhoI sites,
resulting in E6 construct named pcDNA3.1-E6. All the selected
constructs were then sequenced to conﬁrm their identity. Sequences
and the names of constructed plasmids were showed as detailed in
Table 2.
Cell cultures and transfections
SiHa cells and C-33A cells were cultured in DMEM with 10% fetal
bovine serum at 37°C and 5% CO2. Cells were washed with PBS
and switched to antibiotic-free growth medium for 24–48 h before
transfection. Transfections were performed with cells at 80%–90% of
conﬂuence by using of Lipofectamine 2000 (Invitrogen) according to
the manufacturer’s protocol.
To determine whether miRNAs could bind to their putative target
sites in luciferase reporter, C33A cells were co-transfected with
target luciferase reporter or mutated target reporter, and with mat-
ched miRNAs expression vector. The empty pSilencer4.1 vector was
used as a negative control. After 24 h, the cells were harvested for
relative luciferase assay analysis.
To determine the effects of miRNAs on E6 expression from ex-
ogenous plasmids, C33A cells were co-transfected with pcDNA3.1-
E6 vector and miRNAs expression vector. The empty pSilencer4.1
vector was used as control. After 48 h, the cells were collected and
analyzed for E6 mRNA level by RT-PCR.
To determine the effects of miRNAs on endogenous E6 expres-
sion, HPV16-infected cervical cancer SiHa cells were transfected
with miRNAs expression vector or empty pSilencer4.1 vector. Un-
treated SiHa cells were used as another control. After 48 h, the cells
were collected for RT-PCR analysis.
In order to determine whether miRNAs inﬂuence the proliferation
and apoptosis of HPV infected cancer cells, SiHa cells were trans-
fected with miRNAs expression vector or empty pSilencer4.1 vector.
Untreated SiHa cells were used as another control. The cells were
collected for Real time cell analysis (RTCA), Annexin V assay and
Hoechst staining assay.
Luciferase report assays
Luciferase assays were performed 24 h after transfection of C33A
cells using the Dual-Luciferase Reporter Assay System (Promega)
following the manufacturer’s instructions. The mean of the luciferase
activities measured with Luminoskan TL Plus luminometer (Thermo
Labsystems) were used to calculate ratios between Renilla luc-
siferase (F2) and ﬁreﬂy luciferases (F1).
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Total RNA was extracted from cultured cells using Trizol Reagent
(Invitrogen) following the manufacturer’s instructions. For miRNA
analysis, mature miRNAs were reverse transcribed from total RNA
using speciﬁc stem-loop RT primers. Per 15 µL RT reaction includ-
ed: 5× M-MLV buffer, dNTP, M-MLV (200 U), RNase inhibitor (40,
speciﬁc stem–loop RT primers (5 μmol/L), total RNA (1 µg) and H2O.
The mix then incubated at 16°C for 30 min, 42°C for 30 min, 85°C for
5 min, at last the product chilled on ice for 5 min.
For E6 analysis, 1 μg RNA was diluted in H2O along with 1 µL of
Oligo dT Primer (Invitrogen) to obtain a total volume of 12 μL.
Samples were incubated at 65°C for 5 min and chilled on ice for
3 min. Then, 1 μL of RNaseout (Invitrogen), 2 μL 0.1 mol/L dTT
(Invitrogen), and 4 μL 5× First Strand Buffer (Invitrogen) were added
and samples were then incubated at 25°C for 10 min.
Real-time PCR apparatus (CFX96, Bio-Rad), associated with
CFX Manager Software (version 1.6, Bio-Rad), was used for the
real-time PCR. Each reaction was done in duplicate in a volume of
20 µL with 96-well optical-grade PCR plates, sealed with optical
sealing tape (Bio-Rad). Ampliﬁcation reactions were done with
SYBR Green Supermix (Bio-Rad) and following temperature pro-
ﬁles: one cycle at 95°C (3 min), 40 cycles of denaturation at 95°C
(30 s), annealing at 60°C (30 s), extension at 72°C (30 s) and one
ﬁnal cycle at 95°C (30 s). Melt curve analyses were performed by
slowly heating the PCR mixtures from 65°C to 95°C (1°C per cycle
of 10 s) with simultaneous measurements of the SYBR Green I
signal intensities. Relative expressions were calculated by the
formula 2−ΔΔCt.
For semi-quantitative PCR, cDNA was diluted 1:40 in H2O and
1 μL were ampliﬁed in 20 μL with 2× PCR Master Mix using 1 μL of a
10 μmol/L primer mix. The PCR reaction was conducted at 95°C for
3 min, followed by 30 cycles of 95°C for 10 s, 60°C for 30 s and 72°C
for 1 min. The intensities of products obtained were measured by
TotalLab100 software. Primers used in this study were shown in
Table 3.
Real time cell analysis (RTCA)
In order to measure the proliferative potential of cells, SiHa cells
were seeded in a density of 1–2 × 105 cells/well in E-plate according
to the manufacturer’s instructions and were monitored every 4 h
using a real time cell analyzer (RTCA, xCELLigence, Roche). In this
system, cells adhere to the bottom of each well, covering the surface
of the sensor that monitors cells by measuring their cell index that is
translated from the electronic readout. The cell growth curves were
recorded for 120 h to assess the capability of cell proliferation.
Flow cytometric analysis of cell apoptosis
In order to quantify early apoptosis and late apoptosis induced by
miRNAs, cell apoptosis wasmeasured using the Annexin VApoptosis
Detection Kit according to the manufacturer’s protocol. Brieﬂy, at 24 h
after transfectionwith vectors,SiHacellswere trypsinizedandwashed
with cold PBS, and then resuspended in 100 μL 1× binding buffer at
1 × 106 cells/mL. 100 μL of cells were then addedwith 5 μL of Annexin
V and 1 μL of propidium iodide (PI) and were incubated for 15 min at
room temperature in the dark. After incubation, 400 μL 1× binding
bufferwasadded to each tube, and the sampleswereanalyzedby ﬂow
cytometry (Beckman-Coulter) within 1 h.
Hoechst staining assay
In order to examine the nuclear morphological changes in cells, cells
were stained with Hoechst 33258, and visualized by ﬂuorescence
microscope according to the manufacturer’s protocol. Brieﬂy, SiHa
cells were plated with 2.5 × 106 cells/mL in 6-well plates. At 24 h
after transfection, cells were then collected by centrifugation,
washed with phosphate buffered saline (PBS), ﬁxed with
paraformaldehyde and stained with 0.5 mL (10 μg/mL) Hoechst
33258 in darkness for 5 min at room temperature. The results were
observed and recorded under a ﬂuorescence microscope. These
cells exhibited reduced nuclear size, intense ﬂuorescence,
Table 3. Primers used in this study
Target Primer name Primer sequence (5′ to 3′) Application
E6 E6-F AGCGACCCAGAAAGTTACCA QPCR
E6-R GCATAAATCCCGAAAAGCAA










U6 U6-RT CGCTTCACGAATTTGCGTGTCAT RT
U6-F GCTTCGGCAGCACATATACTAAAAT QPCR
Downstream universal primer MiR-R CGCTTCACGAATTTGCGTGTCAT QPCR
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chromatin condensation, and nuclear fragmentation, were consid-
ered apoptotic cells. The percentage of Hoechst-positive apoptotic
cells per visual ﬁeld was determined.
Statistical analysis
All experiments were performed in triplicate in three independent
experiments. The data were tested for signiﬁcance employing the
t-test and presented as mean ± SD. The level of signiﬁcance was set
at P < 0.05.
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